TGFB1 and cardiac hypertrophy: The significant reduction in these key mediators underscores the potential of EV-based strategies to modulate the pathophysiological processes underlying atherosclerosis-associated cardiac hypertrophy, aligning with studies that have targeted the TGF-β1 cascade to alleviate cardiac remodeling [53].